Inventor · disambiguated record
Pieter Rottiers
Also filed as: ROTTIERS PIETER
15 granted patents·6 pending applications·24 citations·filing 2005–2023
90Inventor score
Files withINTREXON ACTOBIOTICS NV6INTREXON ACTOBIOTICS N V5ACTOGENIX NV4ROTTIERS PIETER4ACTOGENIX NV CORP1
Top patents by PatentIndex Score
21 records- 0193US10905727B2Compositions and methods for the treatment of type 1 diabetesINTREXON ACTOBIOTICS N V·Filed 2017·Granted Feb 2, 2021·7 cites·8 claims
- 0292US11786567B2Compositions and methods for the treatment of type 1 diabetesINTREXON ACTOBIOTICS N V·Filed 2021·Granted Oct 17, 2023·2 cites·17 claims
- 0389US10858663B2Genetically modified bacteria stably expressing IL-10 and insulinINTREXON ACTOBIOTICS N V·Filed 2017·Granted Dec 8, 2020·3 cites·31 claims
- 0483US8398995B2Method of inducing immune tolerance to type I diabetesROTTIERS PIETER·Filed 2009·Granted Mar 19, 2013·5 cites·23 claims
- 0582US12246046B2Compositions and methods for the treatment of type 1 diabetesINTREXON ACTOBIOTICS N V·Filed 2023·Granted Mar 11, 2025·0 cites·13 claims
- 0679US12359210B2Genetically modified bacteria stably expressing IL-10 and insulinINTREXON ACTOBIOTICS NV·Filed 2022·Granted Jul 15, 2025·0 cites·14 claims
- 0779US8524246B2Treatment of immune disease by mucosal delivery of antigents using genetically modified LactobacillusACTOGENIX NV·Filed 2012·Granted Sep 3, 2013·3 cites·15 claims
- 0877US9539291B2Induction of mucosal tolerance to antigensINTREXON ACTOBIOTICS NV·Filed 2014·Granted Jan 10, 2017·2 cites·43 claims
- 0977US8748126B2Induction of mucosal tolerance to antigensROTTIERS PIETER·Filed 2006·Granted Jun 10, 2014·2 cites·33 claims
- 1072US10668136B2Treatment of immune disease by mucosal delivery of antigens using genetically modified LactococcusINTREXON ACTOBIOTICS NV·Filed 2018·Granted Jun 2, 2020·0 cites·16 claims
- 1170US11549118B2Genetically modified bacteria stably expressing IL-10 and insulinINTREXON ACTOBIOTICS N V·Filed 2020·Granted Jan 10, 2023·0 cites·17 claims
- 1264US9526750B2Induction of mucosal tolerance to antigensINTREXON ACTOBIOTICS NV·Filed 2014·Granted Dec 27, 2016·0 cites·30 claims
- 1361US10195269B2Induction of mucosal tolerance to antigensINTREXON ACTOBIOTICS NV·Filed 2016·Granted Feb 5, 2019·0 cites·29 claims
- 1461US10143729B2Treatment of immune disease by mucosal delivery of antigens using genetically modified LactococcusINTREXON ACTOBIOTICS NV·Filed 2013·Granted Dec 4, 2018·0 cites·33 claims
- 1560US2010104601A1Treatment of immune disease by mucosal delivery of antigents using genetically modified lactobacillusROTTIERS PIETER·Filed 2008·Application pending·0 cites
- 1651US9017662B2Anti-TNF alpha producing lactic acid bacteria for the treatment of chronic enterocolitisROTTIERS PIETER·Filed 2006·Granted Apr 28, 2015·0 cites·2 claims
- 1750US2010178273A1Methods and compositions for treating mucositisACTOGENIX NV CORP·Filed 2008·Application pending·0 cites
- 1845US2009074734A1Microbial intestinal delivery of obesity related peptidesACTOGENIX NV·Filed 2007·Application pending·0 cites
- 1943US2005276788A1Self-containing lactobacillus strainUNIV GENT·Filed 2005·Application pending·0 cites
- 2041US2008254014A1Use of Recombinant Yeast Strain Producing an Anti-Inflammatory Compound to Treat ColitisACTOGENIX NV·Filed 2006·Application pending·0 cites
- 2138US2010303777A1Delivery of binding molecules to induce immunomodulationACTOGENIX NV·Filed 2007·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →